IDH2 and astrocytoma (excluding glioblastoma): Additionally, WHO grade 2, 3, and 4 IDH-mutant astrocytomas in cluster 1 had significantly higher CIN compared to their grade-matched cluster 2 counterparts, but no other significant clinical or molecular differences (Table 2).